Stocks of Acelyrin Inc (SLRN) are poised to climb above their peers

With 1.48 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.27 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.76 whereas the lowest price it dropped to was $6.32. The 52-week range on SLRN shows that it touched its highest point at $29.88 and its lowest point at $5.70 during that stretch. It currently has a 1-year price target of $31.00.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SLRN was down-trending over the past week, with a drop of -3.83%, but this was down by -21.18% over a month. Three-month performance dropped to -12.66% while six-month performance fell -33.40%. A look at the trailing 12-month EPS for SLRN yields -3.92 with Next year EPS estimates of -4.76. For the next quarter, that number is -0.96. This implies an EPS growth rate of 24.27% for this year and -15.86% for next year.

Float and Shares Shorts:

At present, 97.87 million SLRN shares are outstanding with a float of 60.36 million shares on hand for trading. On Mar 15, 2024, short shares totaled 8.41 million, which was 8.64% higher than short shares on Feb 15, 2024. In addition to Dr. Shao-Lee Lin M.D., Ph.D. as the firm’s Co-Founder, CEO & Director, Ms. Melanie Gloria B.S.N. serves as its Chief Operating Officer.

Institutional Ownership:

Through their ownership of 90.33% of SLRN’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SLRN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, SLRN has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and SLRN currently yields $0.00. In the past year, SLRN’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, SLRN has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.